Breakthrough in COVID-19 Treatment: Arthritis Drug Tocilizumab Shows Promise

Strategic Insights -

Scientists from Imperial College London have been studying an arthritis drug called tocilizumab, which could potentially treat COVID-19 by halting the immune system's "storm" that the body produces in response to infection. The drug, originally developed for rheumatoid arthritis, is being tested on 450 coronavirus patients worldwide. Researchers believe that combining an antiviral with an immune modulator, such as tocilizumab, could be an effective approach to treating patients with severe COVID-19.

Key Takeaways:

  • Tocilizumab, an arthritis drug, is being tested on 450 coronavirus patients worldwide to assess its potential in treating COVID-19.
  • The drug works by stopping the immune system from over-responding and attacking the body, which is a major cause of death in COVID-19 patients.
  • Dr. Taryn Youngstein from Imperial College London stated that the major form of COVID-19 that kills people is related to the body's response to the virus, rather than the virus itself.
  • The drug has been shown to be safe and well-tolerated in its original application for rheumatoid arthritis.
  • Researchers believe that combining an antiviral with an immune modulator like tocilizumab could be an effective approach to treating severe COVID-19 patients.
  • Dr. Levi Garraway, Chief Medical Officer at Roche, expressed optimism about the potential of tocilizumab in treating COVID-19, stating that working together to fight the disease is crucial.
  • The COVID-19 pandemic has resulted in over 16 million cases worldwide, according to current numbers.

Statistics:

  • Over 16 million cases of COVID-19 have been reported worldwide.
  • 45,837 confirmed deaths in the UK.
  • 450 coronavirus patients are being treated with tocilizumab across the world.
  • The drug is being tested globally, with no exact locations specified.

Sources:

  • Imperial College London
  • Daily Mail
  • Roche